commun
acquir
respiratori
viru
infect
carv
includ
varieti
virus
rhinoviru
coronaviru
respiratori
syncyti
viru
rsv
influenza
viru
para
influenza
viru
metapneumo
viru
carv
infect
rang
asymptomat
carriership
signific
respiratori
diseas
preval
carv
larg
depend
season
detect
mode
age
patient
immun
statu
shah
et
al
hirsch
et
al
green
influenza
rsv
signific
season
variat
wherea
para
influenza
rhinoviru
caus
diseas
year
round
green
highli
sensit
diagnost
techniqu
like
polymeras
chain
reaction
pcr
detect
viral
dna
rna
reveal
high
preval
carv
normal
popul
healthi
children
attend
day
care
preval
high
moe
et
al
children
admit
hospit
respiratori
diseas
test
pcr
posit
almost
twice
high
adult
admit
hospit
respiratori
diseas
ching
et
al
immun
compromis
pediatr
popul
preval
carv
around
fazeka
et
al
mostli
mild
symptom
time
detect
mani
report
carv
prior
earli
hematopoiet
cell
transplant
hct
recent
larg
multicent
retrospect
analysi
pediatr
hct
recipi
show
incid
symptomat
carv
infect
within
year
transplant
fisher
et
al
surveil
studi
popul
nasopharyng
aspir
npa
routin
perform
prior
transplant
show
incid
versluy
et
al
studi
discuss
risk
progress
viral
pneumonia
variou
type
carv
group
look
long
term
outcom
result
conflict
report
risk
progress
brediu
et
al
hirsch
et
al
chemali
et
al
fisher
et
al
green
hct
cur
treatment
sever
malign
nonmalign
childhood
diseas
success
limit
infect
alloimmun
toxic
event
respiratori
virus
contribut
posttransplant
morbid
mortal
differ
way
provid
overview
recent
literatur
carv
hct
set
focus
risk
progress
viral
lung
diseas
role
virus
lung
microbiom
potenti
viral
trigger
alloimmun
hct
report
incid
rsv
hctrecipi
vari
shah
et
al
robinson
et
al
fisher
et
al
depend
larg
season
patient
age
detect
method
progress
lrti
occur
shah
et
al
kim
et
al
fisher
et
al
risk
factor
progress
relat
age
donor
sourc
use
steroid
immun
statu
concomit
infect
renaud
et
al
chemali
et
al
kim
et
al
shah
et
al
mortal
rate
around
chemali
et
al
robinson
et
al
fisher
et
al
import
notic
pediatr
studi
rsvposit
patient
treat
antivir
drug
ribavirin
molinosquintana
et
al
antirsv
monoclon
antibodi
palivizumab
nonspecif
intraven
immunoglobulin
ivig
elbietar
et
al
combin
et
al
aerosol
ribavirin
ivig
recommend
adult
hct
recipi
rsv
lrti
dignan
et
al
waghmar
et
al
para
influenza
viru
piv
hct
recipi
systemat
review
shah
et
al
incid
piv
hct
recipi
rang
progress
lrti
signific
predictor
lrti
progress
infect
within
day
hct
lymphocytopenianeutropenia
onset
infect
use
corticosteroid
younger
age
respiratori
coinfect
report
overal
mortal
pivlrti
current
licens
therapi
piv
pneumonia
influenza
diagnos
approxim
hct
recipi
patient
respiratori
symptom
fluseason
progress
viral
pneumonia
occur
patient
associ
mortal
fisher
et
al
green
number
strongli
influenc
season
outbreak
subtyp
influenza
viru
risk
factor
progress
influenza
diseas
lymphocytpenianeutropenia
steroid
use
kmeid
et
al
contrast
mani
respiratori
virus
influenza
treat
neuraminidas
inhibitor
waghmar
et
al
green
human
rhino
viru
hrv
common
caus
respiratori
viru
infect
immunocompet
immunocompromis
individu
report
incid
hct
recipi
versluy
et
al
shah
et
al
campbel
et
al
fisher
et
al
long
time
uncertainti
abil
hrv
caus
lower
respiratori
tract
diseas
recent
studi
howev
suggest
hrv
may
clinic
signific
pathogen
potenti
caus
seriou
pulmonari
diseas
hct
recipi
campbel
et
al
seo
et
al
versluy
et
al
risk
progress
lrti
shah
et
al
campbel
et
al
fisher
et
al
hrv
relat
mortal
shah
et
al
campbel
et
al
fisher
et
al
increas
interest
pathogenec
human
metapneumo
viru
hmpv
systemat
review
shah
et
al
shah
et
al
summar
publish
data
hmpv
patient
hematolog
malign
undergo
hct
one
third
describ
case
children
report
overal
incid
rang
risk
progress
lrti
rang
mortal
rate
total
hmpv
posit
group
hmpvlrti
group
respiratori
virus
like
bocaviru
bov
coronaviru
cov
hct
set
scarc
studi
preval
either
bov
cov
adult
hct
popul
respiratori
symptom
signific
proport
cov
infect
patient
requir
hospit
progress
lrti
contrast
bov
detect
rare
almost
alway
relat
copathogen
pinana
et
al
surveil
studi
bov
children
found
children
rti
pcr
posit
well
healthi
control
thu
show
high
preval
viru
without
necessarili
caus
diseas
progress
lower
infect
howev
associ
higher
bov
load
viremia
suggest
pathogen
role
subgroup
patient
christensen
et
al
figur
show
incid
carv
mainli
adult
hct
popul
impact
carv
lrti
mortal
profound
immunosuppress
patient
undergo
hct
obvious
lead
greater
risk
infect
prolong
shed
viru
higher
chanc
transmiss
diseas
greater
risk
progress
sever
lower
respiratori
tract
diseas
antivir
therapi
effect
minor
respiratori
virus
vaccin
wide
avail
prevent
import
work
group
fourth
european
confer
infect
leukemia
review
literatur
carv
leukem
patient
patient
hct
hirsch
et
al
prevent
recommend
infect
control
measur
like
good
person
hygien
avoid
contact
individu
respiratori
tract
infect
restrict
young
children
visit
patient
administr
ivig
prepar
patient
hypogammaglobulinemia
igg
gl
use
intraven
monoclon
antibodi
specif
rsff
protein
palivizumab
rsv
outbreak
may
consid
advoc
routin
screen
carv
deferr
chemotherapi
condit
consid
well
treatment
rsv
hpiv
hct
set
joint
work
group
uk
dignan
et
al
review
avail
literatur
made
recommend
diagnosi
manag
respiratori
viral
infect
patient
hematolog
malign
undergo
hematopoiet
stem
cell
transplant
far
prevent
concern
come
conclus
add
recommend
influenza
vaccin
household
contact
medic
staff
postexposur
prophylaxi
oseltamivir
hct
patient
contact
influenza
recent
larg
prospect
studi
includ
adult
children
undergo
allogen
hct
clinic
outcom
associ
respiratori
virus
rv
detect
prior
hct
analyz
campbel
et
al
multiplex
pcr
test
rv
done
nasal
wash
nasopharyng
swab
patient
rv
detect
asymptomat
pediatr
subgroup
defin
age
year
preval
rv
higher
larger
proport
without
symptom
rv
posit
patient
significantli
younger
higher
risk
underli
diseas
lower
lymphocyt
count
overal
mortal
day
significantli
higher
rvpatient
nonrv
patient
vs
hr
ci
p
deceas
patient
caus
death
thought
directli
relat
prehct
rv
data
given
caus
death
patient
patient
rhinoviru
perform
wors
compar
rv
may
partli
explain
fact
patient
rsv
influenza
treat
antivir
therapi
transplant
delay
data
longer
follow
lack
campbel
et
al
hutspardol
et
al
retrospect
studi
treatment
relat
mortal
trm
longterm
pulmonari
complic
children
respiratori
symptom
rv
detect
within
day
allogen
hct
overal
frequenc
document
rv
infect
half
patient
present
sign
lrti
mortal
rate
day
caus
death
pneumonitisard
symptom
occur
day
hct
follow
year
rang
chronic
pulmonari
complic
alloimmun
lung
syndrom
observ
hutspardol
et
al
regard
long
term
pulmonari
function
chien
et
al
studi
adult
hct
recipi
perform
routin
pulmonari
function
test
year
hct
airflow
obstruct
defin
annual
declin
occur
patient
impact
overal
mortal
higher
age
transplant
gvhd
categori
pulmonari
function
pretranspl
occurr
respiratori
viru
infect
within
first
day
hct
signific
risk
factor
airflow
obstruct
chien
et
al
erard
et
al
studi
associ
rv
airflow
declin
found
particularli
true
patient
lrti
caus
parainfluenza
viru
respiratori
syncyti
viru
erard
et
al
retrospect
studi
among
pediatr
hct
recipi
us
center
acquir
symptomat
rv
within
first
year
hct
fisher
et
al
line
other
rhinoviru
common
viru
follow
rsv
piv
rv
detect
median
day
hct
children
urti
patient
hmpv
significantli
lrti
month
follow
requir
mechan
ventil
signific
pulmonari
sequela
like
bronchiol
obliteran
subacut
pulmonari
problem
specifi
pulmonari
complic
caus
mortal
among
rv
posit
patient
compar
noncarv
group
recent
steroid
exposur
rv
detect
within
day
hct
poor
prognost
factor
morbid
death
least
death
attribut
carv
infect
time
event
also
remark
death
occur
day
diagnos
carv
infect
least
month
hct
widespread
use
pcr
diagnost
led
increas
detect
carv
patient
undergo
hct
mani
patient
becom
symptomat
signific
proport
develop
lrti
clear
increas
risk
mortal
carv
posit
patient
henc
prevent
develop
antivir
drug
great
import
howev
one
could
debat
reason
sever
morbid
mortal
carv
posit
patient
diagnos
progress
viral
infect
carv
clear
month
immunocompromis
state
host
hct
find
posit
pcr
convinc
enough
time
progress
symptom
relat
immun
reconstitut
might
help
answer
question
progress
viral
damag
donor
deriv
immun
actual
target
lung
last
decad
evid
emerg
trigger
alloreact
may
play
crucial
role
toxic
mortal
hold
true
hct
also
recogn
solid
organ
transplant
context
lung
transplant
sever
studi
examin
role
rv
develop
chronic
lung
allograft
dysfunct
clad
form
chronic
reject
lung
kumar
et
al
fisher
et
al
mani
report
associ
rv
clad
pool
analys
studi
rv
clad
vu
et
al
confirm
associ
mainli
due
heterogen
studi
limit
design
diagnost
techniqu
definit
fisher
et
al
tri
overcom
limit
studi
homogen
cohort
lung
transplant
recipi
use
modern
molecular
assay
detect
rv
appli
consensu
definit
clad
fisher
et
al
patient
develop
clad
median
week
interquartil
rang
iqr
week
patient
respiratori
viral
episod
seen
median
week
post
lung
transplant
iqr
week
multivari
analysi
rv
associ
clad
ci
p
associ
stronger
proxim
rv
occur
lung
transplant
group
studi
role
respiratori
virus
rv
immun
mediat
lung
diseas
hct
analog
phenomenon
describ
lung
transplant
versluy
et
al
hostv
graft
chronic
allograft
reject
lung
transplant
mani
way
compar
graftv
host
inflamm
hematopoiet
cell
transplant
cohort
children
undergo
allogen
hct
routin
npa
bal
sampl
presenc
rv
done
prior
transplant
rv
found
balnpa
npaonli
rhinoviru
frequent
detect
rv
alloimmun
lung
syndrom
allol
defin
bronchiol
obliteran
syndrom
bo
idiopath
pneumonia
syndrom
ip
occur
median
week
week
rvposit
bal
predictor
allol
hr
ci
p
predictor
found
hypothesi
rv
caus
epitheli
damag
trigger
allogen
immun
respons
lead
sever
lung
diseas
lung
diseas
occur
primarili
progress
viral
infect
period
low
immun
alloimmun
mediat
damag
week
hct
inflammatori
aspect
diseas
might
explain
report
benefit
steroid
use
risk
mechan
ventil
among
hct
recipi
influenza
choi
et
al
controversi
risk
steroid
use
case
carv
hct
waghmar
et
al
known
role
microbiota
human
health
far
research
larg
focus
gut
microbiom
also
context
gvhd
microbi
ecosystem
bodi
site
includ
respiratori
tract
attract
grow
attent
host
environment
factor
influenc
respiratori
microbiota
includ
genet
microbi
exposur
birth
mode
feed
type
day
care
vaccin
infect
antibiot
man
et
al
viral
infect
interact
microbiom
disrupt
airway
epitheli
barrier
facilit
bacteri
adhes
liber
host
deriv
nutrient
decreas
mucociliari
clearanc
addit
respiratori
virus
modul
innat
adapt
immun
respons
promot
bacteri
colon
man
et
al
moreov
becom
clear
virom
seen
part
microbiom
affect
function
host
immun
system
cadwel
role
disturb
respiratori
microbiomevirom
lung
diseas
postul
asthma
chronic
obstruct
pulmonari
diseas
copd
zou
et
al
impact
carv
outcom
hct
intrigu
topic
pathogenesi
complet
understood
poor
immun
system
associ
progress
infect
alloimmun
play
crucial
role
lung
toxic
studi
describ
data
symptomat
patient
carv
detect
time
symptom
studi
report
prehct
sampl
although
know
larg
proport
patient
carv
posit
mild
symptom
time
worsen
symptom
warrant
viral
diagnost
thu
detect
carv
often
week
hct
nosocomi
acquir
virus
viru
alreadi
present
give
symptom
certain
period
time
virus
acquir
discharg
immun
usual
restor
certain
degre
variou
infecti
diseas
like
rsv
bronchiol
fonseca
et
al
immun
reconstitut
inflammatori
syndrom
iri
hiv
patient
cryptococc
mening
cmv
retin
bcgiti
walker
et
al
iri
nonhiv
immunesuppress
patient
immun
recoveri
follow
worsen
treat
tuberculosi
idiopat
pneumonia
hepat
sueki
et
al
know
harm
effect
immun
respons
patient
debat
inappropri
immun
respons
infecti
trigger
especi
intrigu
allogen
set
definit
criteria
alloimmun
mediat
lung
syndrom
panoskaltsismortari
et
al
jagasia
et
al
describ
clinic
radiolog
function
aspect
lung
patholog
exclus
evid
caus
phenotyp
like
heart
failur
infect
includ
respiratori
viru
infect
one
argu
hold
true
respiratori
virus
detect
pcr
detect
mode
becom
much
sensit
time
impact
posit
find
diseas
criteria
reevalu
hct
popul
high
preval
rv
virus
long
persist
make
detect
week
initi
infect
uncertain
mean
role
patholog
interest
paper
matter
recent
publish
seo
et
al
patient
ip
went
back
bal
sampl
time
diagnosi
appli
sensit
diagnost
microbi
pathogen
patient
occult
pathogen
found
respiratori
viru
patient
treat
steroid
ip
overal
mortal
higher
group
patient
occult
pathogen
group
without
author
conclud
patient
exclud
ip
patient
infecti
pneumonia
steroid
treatment
advers
influenc
outcom
howev
inform
rv
statu
prehct
could
also
persist
rv
hct
trigger
immunemedi
lung
diseas
ip
situat
steroid
benefici
treatment
moment
clinic
deterior
conclus
despit
grow
awar
carv
infect
hct
patient
welldesign
studi
lack
systemat
evalu
diagnost
therapeut
strategi
carv
abl
better
understand
direct
viral
impact
indirect
alloimmun
patholog
larg
influenc
clinic
outcom
patient
detail
longitudin
studi
combin
data
microbiomavirioma
surveil
data
immunerecoveri
hct
clinic
outcom
need
better
understand
pathogen
mechan
involv
lung
diseas
carv
hct
insight
larg
influenc
therapeut
decis
delay
transplant
treat
rv
import
increas
decreas
immun
suppress
transplant
review
pv
declar
past
coauthorship
one
author
jb
handl
editor
remain
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
